Phase I study of polyhexanide seeks safety, tolerability characteristics for patients with AK
February 1st 2021The study focused the safety and tolerability of increasing doses of polihexanide eye drops in order to choose a dose that would be tested in a phase III clinical trial in patients with acanthamoeba keratitis.
Read More
Glaukos COO shares product updates, 2021 pipeline
January 31st 2021Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.
Read More
First patient dosed in Phase I clinical trial of wet AMD treatment candidate
January 28th 2021The Phase 1 clinical trial of EyePoint Pharmaceuticals Inc.’s EYP-1901 is underway. It is a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration.
Read More
Enrollment completed for first Phase 3 study of perfluorohexyloctane
January 19th 2021Bausch + Lomb has enrolled 599 participants in the first of two Phase 3 studies evaluating perfluorohexyloctane as a first-in-class investigational drug to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction.
Read More
As COVID-19 focuses attention on vaccine, medication shortages loom
January 14th 2021Amid ramped up production of vaccines, CARES Act gives FDA power to head off potential drug shortfalls. Prevent Blindness is urging the FDA to use its authority to ensure TED treatment drug supply isn’t interrupted.
Read More
Collaboration formed to develop AAV-based gene therapies for eye disease
January 6th 2021ViGeneron and Biogen this week have announced a global collaboration and licensing agreement in which the partners will develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors that treat inherited eye disease.
Read More
Visual outcomes of small-aperture IOL implant in post-laser refractive eyes
December 17th 2020Robert Ang, MD, discusses highlights of his AAO 2020 presentation on a study analyzing the vIsual outcomes of a small-aperture IOL implantation in patients with a history of post-laser refractive surgery.
Read More
Analysis of investigational ophthalmic solution for treating presbyopia-related symptoms
December 13th 2020Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.
Read More
Evaluating long-term safety of micro-bypass implant with phaco in PXG
December 12th 2020Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.
Read More